Clinical Trial Update: Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus [Phase 2]

View source ↗

Summary

This update reports the termination of a Phase 2 trial of topotecan in patients with recurrent or refractory uterine cancer (uterine sarcoma).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Sarcoma

Drugs mentioned

• Topotecan (topotecan)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Sarcoma | Phase 2 | Status: TERMINATED